Details of the Drug

General Information of Drug (ID: DMK7F9S)

Drug Name
Amitriptyline
Synonyms
Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2], [3]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 277.4
Topological Polar Surface Area (xlogp) 5
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 100% [5]
Clearance
The sytemic clearance of drug is 39.24 +/- 10.18 L/h [6]
Elimination
Virtually the entire dose is excreted as glucuronide or sulfate conjugate of metabolites, with approximately 2% of unchanged drug appearing in the urine [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 25 hours [8]
Metabolism
The drug is metabolized via the demethylation (CYP2C19, CYP3A4) as well as hydroxylation (CYP2D6) followed by conjugation with glucuronic acid [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.4494 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.07% [10]
Vd
The volume of distribution (Vd) of drug is 1221 L +/- 280 L [6]
Water Solubility
The ability of drug to dissolve in water is measured as 1000 mg/mL [4]
Chemical Identifiers
Formula
C20H23N
IUPAC Name
N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
Canonical SMILES
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
InChI
InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
InChIKey
KRMDCWKBEZIMAB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2160
ChEBI ID
CHEBI:2666
CAS Number
50-48-6
DrugBank ID
DB00321
TTD ID
D0Y5UG
VARIDT ID
DR00470
INTEDE ID
DR0095
ACDINA ID
D00032

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [11], [12]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [11], [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [15]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [14]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [16]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [17]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [18]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [19]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [20]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [21]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [22]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
P-glycoprotein 1 (ABCB1) DTP P-GP 6.54E-01 1.95E-01 4.04E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 4.53E-01 4.14E-02 1.83E-01
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 9.45E-02 -1.86E-01 -9.83E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.57E-01 -7.89E-02 -7.93E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.32E-01 4.39E-02 4.30E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.46E-01 -6.63E-03 -4.49E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.57E-01 9.43E-03 1.29E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 9.62E-01 2.57E-02 1.10E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amitriptyline
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Amitriptyline and Trimipramine. Depression [6A70-6A7Z] [122]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Imipramine. Depression [6A70-6A7Z] [122]
Fluoxetine DM3PD2C Major Decreased metabolism of Amitriptyline caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [123]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Amitriptyline and Nortriptyline. Depression [6A70-6A7Z] [122]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Amitriptyline and Vilazodone. Depression [6A70-6A7Z] [124]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Amitriptyline and Nefazodone. Depression [6A70-6A7Z] [124]
Paroxetine DM5PVQE Major Decreased metabolism of Amitriptyline caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [125]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Amitriptyline and Selegiline. Depression [6A70-6A7Z] [126]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Amitriptyline and Vortioxetine. Depression [6A70-6A7Z] [124]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Amitriptyline and Duloxetine. Depression [6A70-6A7Z] [124]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Amitriptyline and Isocarboxazid. Depression [6A70-6A7Z] [126]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Amitriptyline and Milnacipran. Depression [6A70-6A7Z] [124]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Amitriptyline and Escitalopram. Depression [6A70-6A7Z] [127]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Amitriptyline and Tranylcypromine. Depression [6A70-6A7Z] [126]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Amitriptyline and Desvenlafaxine. Depression [6A70-6A7Z] [124]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Amitriptyline and OPC-34712. Depression [6A70-6A7Z] [122]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Amitriptyline and Phenelzine. Depression [6A70-6A7Z] [126]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Amitriptyline and Clomipramine. Depression [6A70-6A7Z] [122]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Amitriptyline and Trazodone. Depression [6A70-6A7Z] [124]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Amitriptyline and Amoxapine. Depression [6A70-6A7Z] [122]
Mirtazapine DML53ZJ Major Additive serotonergic effects by the combination of Amitriptyline and Mirtazapine. Depression [6A70-6A7Z] [124]
Protriptyline DMNHTZI Moderate Additive anticholinergic effects by the combination of Amitriptyline and Protriptyline. Depression [6A70-6A7Z] [122]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Amitriptyline and Doxepin. Depression [6A70-6A7Z] [122]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Amitriptyline and Maprotiline. Depression [6A70-6A7Z] [122]
⏷ Show the Full List of 24 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Amitriptyline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Amitriptyline and Methylene blue. Acquired methaemoglobinaemia [3A93] [126]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Ivosidenib. Acute myeloid leukaemia [2A60] [128]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Midostaurin. Acute myeloid leukaemia [2A60] [129]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Idarubicin. Acute myeloid leukaemia [2A60] [129]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Daunorubicin. Acute myeloid leukaemia [2A60] [129]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Arn-509. Acute myeloid leukaemia [2A60] [130]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Gilteritinib. Acute myeloid leukaemia [2A60] [131]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Amitriptyline and Oliceridine. Acute pain [MG31] [132]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Amitriptyline and Scopolamine. Addictive disorder [6C50-6C5Z] [122]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [129]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Amitriptyline and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [133]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Amitriptyline and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [133]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [122]
Tacrine DM51FY6 Moderate Antagonize the effect of Amitriptyline when combined with Tacrine. Alzheimer disease [8A20] [134]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Amitriptyline and Memantine. Alzheimer disease [8A20] [122]
Galantamine DMEO794 Moderate Antagonize the effect of Amitriptyline when combined with Galantamine. Alzheimer disease [8A20] [134]
Rivastigmine DMG629M Moderate Antagonize the effect of Amitriptyline when combined with Rivastigmine. Alzheimer disease [8A20] [134]
Donepezil DMIYG7Z Moderate Antagonize the effect of Amitriptyline when combined with Donepezil. Alzheimer disease [8A20] [134]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Amitriptyline and Metronidazole. Amoebiasis [1A36] [135]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Ivabradine. Angina pectoris [BA40] [130]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Bepridil. Angina pectoris [BA40] [136]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Dronedarone. Angina pectoris [BA40] [129]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Amitriptyline and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [137]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Amitriptyline and Buspirone. Anxiety disorder [6B00-6B0Z] [124]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [122]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Amitriptyline caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [138]
Promazine DMZAL7W Moderate Increased plasma concentrations of Amitriptyline and Promazine due to competitive inhibition of the same metabolic pathway. Appearance/behaviour symptom [MB23] [139]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Cilostazol. Arterial occlusive disease [BD40] [129]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Voriconazole. Aspergillosis [1F20] [129]
Methylphenidate DM7SJD6 Moderate Decreased metabolism of Amitriptyline caused by Methylphenidate. Attention deficit hyperactivity disorder [6A05] [140]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Amitriptyline and Desipramine. Attention deficit hyperactivity disorder [6A05] [122]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Ofloxacin. Bacterial infection [1A00-1C4Z] [141]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [129]
Dalfopristin DM4LTKV Major Decreased metabolism of Amitriptyline caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [142]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Amitriptyline and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [129]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Amitriptyline and Sparfloxacin. Bacterial infection [1A00-1C4Z] [141]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Amitriptyline and Linezolid. Bacterial infection [1A00-1C4Z] [143]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Gemifloxacin. Bacterial infection [1A00-1C4Z] [141]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Norfloxacin. Bacterial infection [1A00-1C4Z] [141]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Levofloxacin. Bacterial infection [1A00-1C4Z] [141]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Lomefloxacin. Bacterial infection [1A00-1C4Z] [129]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Telithromycin. Bacterial infection [1A00-1C4Z] [129]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Retigabine. Behcet disease [4A62] [129]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Amitriptyline and Cariprazine. Bipolar disorder [6A60] [122]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Amitriptyline and Loperamide. Bowel habit change [ME05] [144]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Eribulin. Breast cancer [2C60-2C6Y] [129]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Lapatinib. Breast cancer [2C60-2C6Y] [129]
Alpelisib DMEXMYK Moderate Increased metabolism of Amitriptyline caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [145]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Tamoxifen. Breast cancer [2C60-2C6Y] [129]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Amitriptyline and Toremifene. Breast cancer [2C60-2C6Y] [129]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Amitriptyline and Grepafloxacin. Bronchitis [CA20] [141]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Amitriptyline and Sotalol. Cardiac arrhythmia [BC9Z] [129]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Amitriptyline when combined with Acetylcholine. Cataract [9B10] [146]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [147]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [148]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Amitriptyline and Tiotropium. Chronic obstructive pulmonary disease [CA22] [148]
Ipratropium DMFQ320 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Ipratropium. Chronic obstructive pulmonary disease [CA22] [148]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Amitriptyline and Revefenacin. Chronic obstructive pulmonary disease [CA22] [148]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Amitriptyline and Dihydrocodeine. Chronic pain [MG30] [132]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Amitriptyline and Levomilnacipran. Chronic pain [MG30] [124]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Oxaliplatin. Colorectal cancer [2B91] [129]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Amitriptyline and Olopatadine. Conjunctiva disorder [9A60] [149]
Mestranol DMG3F94 Minor Decreased metabolism of Amitriptyline caused by Mestranol. Contraceptive management [QA21] [150]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Halothane. Corneal disease [9A76-9A78] [129]
Alfentanil DMVO0UB Moderate Additive serotonergic effects by the combination of Amitriptyline and Alfentanil. Corneal disease [9A76-9A78] [132]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Amitriptyline and Remifentanil. Corneal disease [9A76-9A78] [132]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Probucol. Coronary atherosclerosis [BA80] [129]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Amitriptyline and Methadone. Cough [MD12] [129]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Clofazimine. Crohn disease [DD70] [151]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Amitriptyline and Mifepristone. Cushing syndrome [5A70] [129]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Osilodrostat. Cushing syndrome [5A70] [130]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Amitriptyline and Ethanol. Cystitis [GC00] [152]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Amitriptyline and Hyoscyamine. Digestive system disease [DE2Z] [122]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Amitriptyline and Mepenzolate. Digestive system disease [DE2Z] [122]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Amitriptyline and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [153]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Amitriptyline and Oxybutynine. Discovery agent [N.A.] [122]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [129]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Meclizine. Dizziness and giddiness [MB48] [122]
Trihexyphenidyl DMB19L8 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Trihexyphenidyl. Dystonic disorder [8A02] [122]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Amitriptyline and Deutetrabenazine. Dystonic disorder [8A02] [154]
Fenfluramine DM0762O Moderate Additive serotonergic effects by the combination of Amitriptyline and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [155]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Amitriptyline and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [156]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Amitriptyline caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [135]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Amitriptyline caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [157]
Carbamazepine DMZOLBI Moderate Antagonize the effect of Amitriptyline when combined with Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [158]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Amitriptyline and Diphenhydramine. Episodic vestibular syndrome [AB31] [122]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Amitriptyline and Solifenacin. Functional bladder disorder [GC50] [122]
Mirabegron DMS1GYT Moderate Decreased metabolism of Amitriptyline caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [159]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Tolterodine. Functional bladder disorder [GC50] [122]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Amitriptyline caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [160]
Itraconazole DMCR1MV Moderate Decreased metabolism of Amitriptyline caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [161]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Pentamidine. Fungal infection [1F29-1F2F] [129]
Terbinafine DMI6HUW Moderate Decreased metabolism of Amitriptyline caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [162]
Miconazole DMPMYE8 Moderate Decreased metabolism of Amitriptyline caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [161]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Amitriptyline and Propantheline. Gastric ulcer [DA60] [122]
Cimetidine DMH61ZB Moderate Decreased metabolism of Amitriptyline caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [163]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Amitriptyline and Cisapride. Gastro-oesophageal reflux disease [DA22] [129]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Sunitinib. Gastrointestinal stromal tumour [2B5B] [129]
Acetazolamide DM1AF5U Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Amitriptyline caused by Acetazolamide mediated altered urine pH. Glaucoma [9C61] [164]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Amitriptyline when combined with Isoflurophate. Glaucoma [9C61] [146]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Amitriptyline and Brimonidine. Glaucoma [9C61] [165]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Amitriptyline when combined with Pilocarpine. Glaucoma [9C61] [146]
Carvedilol DMHTEAO Moderate Increased plasma concentrations of Amitriptyline and Carvedilol due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [157]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Amitriptyline and Procarbazine. Hodgkin lymphoma [2B30] [126]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Amitriptyline caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [166]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [167]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Amitriptyline caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [168]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Amitriptyline and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [169]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Amitriptyline and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [170]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [129]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Amitriptyline caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [166]
Atazanavir DMSYRBX Moderate Decreased metabolism of Amitriptyline caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [166]
Ritonavir DMU764S Moderate Decreased metabolism of Amitriptyline caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [171]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Amitriptyline caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [135]
Verapamil DMA7PEW Moderate Decreased metabolism of Amitriptyline caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [172]
Labetalol DMK8U72 Moderate Increased plasma concentrations of Amitriptyline and Labetalol due to competitive inhibition of the same metabolic pathway. Hypertension [BA00-BA04] [157]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Amitriptyline and Belladonna. Infectious gastroenteritis/colitis [1A40] [122]
Propiomazine DMKY8V1 Moderate Increased plasma concentrations of Amitriptyline and Propiomazine due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [139]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Amitriptyline and ITI-007. Insomnia [7A00-7A0Z] [122]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Polyethylene glycol. Irritable bowel syndrome [DD91] [129]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Clidinium. Irritable bowel syndrome [DD91] [122]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Amitriptyline and Dicyclomine. Irritable bowel syndrome [DD91] [122]
Physostigmine DM2N0TO Moderate Antagonize the effect of Amitriptyline when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [134]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Amitriptyline caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [130]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Amitriptyline and Ceritinib. Lung cancer [2C25] [129]
PF-06463922 DMKM7EW Moderate Increased metabolism of Amitriptyline caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [173]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Amitriptyline caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [174]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Amitriptyline and Osimertinib. Lung cancer [2C25] [175]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Amitriptyline and Halofantrine. Malaria [1F40-1F45] [176]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Amitriptyline and Chloroquine. Malaria [1F40-1F45] [177]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Amitriptyline and Hydroxychloroquine. Malaria [1F40-1F45] [177]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Quinine. Malaria [1F40-1F45] [129]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Primaquine. Malaria [1F40-1F45] [129]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [130]
IPI-145 DMWA24P Moderate Decreased metabolism of Amitriptyline caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [178]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Arsenic trioxide. Mature B-cell lymphoma [2A85] [179]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Vemurafenib. Melanoma [2C30] [129]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and LGX818. Melanoma [2C30] [180]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Amitriptyline caused by Ethinyl estradiol. Menopausal disorder [GA30] [150]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Amitriptyline and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [181]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Amitriptyline and Flibanserin. Mood disorder [6A60-6E23] [182]
Doxylamine DMKOXFE Moderate Additive anticholinergic effects by the combination of Amitriptyline and Doxylamine. Morning sickness disorder [SC00] [122]
Riluzole DMECBWN Minor Decreased metabolism of Amitriptyline caused by Riluzole mediated inhibition of CYP450 enzyme. Motor neuron disease [8B60] [183]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Amitriptyline and Panobinostat. Multiple myeloma [2A83] [184]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Amitriptyline and Thalidomide. Multiple myeloma [2A83] [185]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Siponimod. Multiple sclerosis [8A40] [135]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Fingolimod. Multiple sclerosis [8A40] [129]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Amitriptyline and Ozanimod. Multiple sclerosis [8A40] [186]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Romidepsin. Mycosis fungoides [2B01] [129]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Amitriptyline caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [130]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Amitriptyline and Nilotinib. Myeloproliferative neoplasm [2A20] [129]
Imatinib DM7RJXL Moderate Decreased metabolism of Amitriptyline caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [187]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Dasatinib. Myeloproliferative neoplasm [2A20] [188]
Modafinil DMYILBE Moderate Decreased metabolism of Amitriptyline caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [135]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Amitriptyline and Phenindamine. Nasopharyngitis [CA00] [122]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Droperidol. Nausea/vomiting [MD90] [129]
Prochlorperazine DM53SRA Moderate Increased plasma concentrations of Amitriptyline and Prochlorperazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [139]
Promethazine DM6I5GR Moderate Increased plasma concentrations of Amitriptyline and Promethazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [139]
Rolapitant DM8XP26 Moderate Decreased metabolism of Amitriptyline caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [189]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Amitriptyline and Cyclizine. Nausea/vomiting [MD90] [122]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Amitriptyline and Palonosetron. Nausea/vomiting [MD90] [129]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Amitriptyline and Granisetron. Nausea/vomiting [MD90] [129]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Amitriptyline and Ondansetron. Nausea/vomiting [MD90] [129]
Thiethylperazine DMU3IET Moderate Increased plasma concentrations of Amitriptyline and Thiethylperazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [139]
Bupropion DM5PCS7 Major Decreased metabolism of Amitriptyline caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [129]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Entrectinib. Non-small cell lung cancer [2C25] [135]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Amitriptyline and Sibutramine. Obesity [5B80-5B81] [190]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Amitriptyline and Lorcaserin. Obesity [5B80-5B81] [191]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Amitriptyline and Dexfenfluramine. Obesity [5B80-5B81] [124]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Levomethadyl Acetate. Opioid use disorder [6C43] [130]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Amitriptyline and Lofexidine. Opioid use disorder [6C43] [130]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Amitriptyline and Apraclonidine. Optic nerve disorder [9C40] [192]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Rucaparib. Ovarian cancer [2C73] [129]
Altretamine DMKLAYG Moderate Additive hypotensive effects by the combination of Amitriptyline and Altretamine. Ovarian cancer [2C73] [193]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Amitriptyline and Pentazocine. Pain [MG30-MG3Z] [132]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Amitriptyline and Dextropropoxyphene. Pain [MG30-MG3Z] [194]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Amitriptyline and Butorphanol. Pain [MG30-MG3Z] [132]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Amitriptyline and Oxymorphone. Pain [MG30-MG3Z] [132]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Amitriptyline and Levorphanol. Pain [MG30-MG3Z] [132]
Hydromorphone DMHP21E Moderate Additive CNS depression effects by the combination of Amitriptyline and Hydromorphone. Pain [MG30-MG3Z] [132]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Amitriptyline and Dezocine. Pain [MG30-MG3Z] [132]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Amitriptyline and Flavoxate. Pain [MG30-MG3Z] [122]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Amitriptyline and Nalbuphine. Pain [MG30-MG3Z] [132]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Amitriptyline and Buprenorphine. Pain [MG30-MG3Z] [132]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Amitriptyline and Hydrocodone. Pain [MG30-MG3Z] [132]
Meperidine DMX4GND Major Additive serotonergic effects by the combination of Amitriptyline and Meperidine. Pain [MG30-MG3Z] [124]
Oxycodone DMXLKHV Moderate Additive serotonergic effects by the combination of Amitriptyline and Oxycodone. Pain [MG30-MG3Z] [132]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Triclabendazole. Parasitic worm infestation [1F90] [129]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Amitriptyline and Safinamide. Parkinsonism [8A00] [186]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Amitriptyline and Rasagiline. Parkinsonism [8A00] [126]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Amitriptyline and Biperiden. Parkinsonism [8A00] [122]
Procyclidine DMHFJDT Moderate Additive anticholinergic effects by the combination of Amitriptyline and Procyclidine. Parkinsonism [8A00] [122]
Levodopa DMN3E57 Minor Altered absorption of Amitriptyline due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [195]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Pimavanserin. Parkinsonism [8A00] [196]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Amitriptyline and Orphenadrine. Parkinsonism [8A00] [122]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Apomorphine. Parkinsonism [8A00] [129]
Abametapir DM2RX0I Moderate Decreased metabolism of Amitriptyline caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [197]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Amitriptyline and Lindane. Pediculosis [1G00] [198]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Amitriptyline and Methylscopolamine. Peptic ulcer [DA61] [122]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Famotidine. Peptic ulcer [DA61] [135]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Amitriptyline and Macimorelin. Pituitary gland disorder [5A60-5A61] [199]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Lefamulin. Pneumonia [CA40] [200]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Degarelix. Prostate cancer [2C82] [130]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and ABIRATERONE. Prostate cancer [2C82] [130]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Nilutamide. Prostate cancer [2C82] [130]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Enzalutamide. Prostate cancer [2C82] [130]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Flutamide. Prostate cancer [2C82] [130]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Bicalutamide. Prostate cancer [2C82] [130]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Amitriptyline and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [139]
Fluphenazine DMIT8LX Moderate Increased plasma concentrations of Amitriptyline and Fluphenazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [139]
Triflupromazine DMKFQJP Moderate Increased plasma concentrations of Amitriptyline and Triflupromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [139]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Sorafenib. Renal cell carcinoma [2C90] [129]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Gatifloxacin. Respiratory infection [CA07-CA4Z] [201]
Celecoxib DM6LOQU Moderate Decreased metabolism of Amitriptyline caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [202]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Cyproheptadine. Rheumatoid arthritis [FA20] [122]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Quetiapine. Schizophrenia [6A20] [129]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Amitriptyline and Mesoridazine. Schizophrenia [6A20] [129]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Amitriptyline and Thioridazine. Schizophrenia [6A20] [203]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Amitriptyline and Aripiprazole. Schizophrenia [6A20] [122]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Amitriptyline and Iloperidone. Schizophrenia [6A20] [129]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Paliperidone. Schizophrenia [6A20] [129]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Amitriptyline and Loxapine. Schizophrenia [6A20] [122]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Haloperidol. Schizophrenia [6A20] [204]
Perphenazine DMA4MRX Moderate Increased plasma concentrations of Amitriptyline and Perphenazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [139]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Amitriptyline and Molindone. Schizophrenia [6A20] [122]
Chlorpromazine DMBGZI3 Moderate Increased plasma concentrations of Amitriptyline and Chlorpromazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [139]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Thiothixene. Schizophrenia [6A20] [122]
Trifluoperazine DMKBYWI Moderate Increased plasma concentrations of Amitriptyline and Trifluoperazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [139]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Amitriptyline and Risperidone. Schizophrenia [6A20] [122]
Olanzapine DMPFN6Y Moderate Additive anticholinergic effects by the combination of Amitriptyline and Olanzapine. Schizophrenia [6A20] [122]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Amitriptyline and Amisulpride. Schizophrenia [6A20] [205]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Asenapine. Schizophrenia [6A20] [129]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Amitriptyline and Pimozide. Schizophrenia [6A20] [130]
Sufentanil DMU7YEL Moderate Additive CNS depression effects by the combination of Amitriptyline and Sufentanil. Sensation disturbance [MB40] [132]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Vardenafil. Sexual dysfunction [HA00-HA01] [129]
Armodafinil DMGB035 Moderate Decreased metabolism of Amitriptyline caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [135]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Amitriptyline and LEE011. Solid tumour/cancer [2A00-2F9Z] [129]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [129]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Amitriptyline and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [129]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [130]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [129]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [129]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Adenosine. Supraventricular tachyarrhythmia [BC81] [129]
Fostamatinib DM6AUHV Moderate Decreased clearance of Amitriptyline due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [206]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Lenvatinib. Thyroid cancer [2D10] [129]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Cabozantinib. Thyroid cancer [2D10] [130]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Amitriptyline and Papaverine. Tonus and reflex abnormality [MB47] [207]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Amitriptyline and Tizanidine. Tonus and reflex abnormality [MB47] [208]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Tacrolimus. Transplant rejection [NE84] [129]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Atropine. Unspecific substance harmful effect [NE6Z] [122]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Astemizole. Vasomotor/allergic rhinitis [CA08] [129]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Amitriptyline and Triprolidine. Vasomotor/allergic rhinitis [CA08] [122]
Methdilazine DMAUHQX Moderate Increased plasma concentrations of Amitriptyline and Methdilazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [139]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Amitriptyline and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [122]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Amitriptyline and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [209]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Amitriptyline and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [122]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Amitriptyline and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [122]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Amitriptyline and Cetirizine. Vasomotor/allergic rhinitis [CA08] [210]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Amitriptyline and Acrivastine. Vasomotor/allergic rhinitis [CA08] [122]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Amitriptyline and Azatadine. Vasomotor/allergic rhinitis [CA08] [122]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Procainamide. Ventricular tachyarrhythmia [BC71] [129]
Propafenone DMPIBJK Moderate Decreased metabolism of Amitriptyline caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [211]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Amitriptyline and Flecainide. Ventricular tachyarrhythmia [BC71] [211]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Amitriptyline and Amiodarone. Ventricular tachyarrhythmia [BC71] [129]
⏷ Show the Full List of 264 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA E00607 135423095 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Amitriptyline 10 mg tablet 10 mg Oral Tablet Oral
Amitriptyline 100 mg tablet 100 mg Oral Tablet Oral
Amitriptyline 150 mg tablet 150 mg Oral Tablet Oral
Amitriptyline 25 mg tablet 25 mg Oral Tablet Oral
Amitriptyline 50 mg tablet 50 mg Oral Tablet Oral
Amitriptyline 75 mg tablet 75 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 200).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
4 BDDCS applied to over 900 drugs
5 Norwegian Food Safety Authority: Methyl salicylate risk review
6 Bryson HM, Wilde MI: Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996 Jun;8(6):459-76. doi: 10.2165/00002512-199608060-00008.
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
12 A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90.
13 Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
14 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
15 Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998 Feb;38(2):112-21.
16 Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
17 Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
18 A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
19 The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J. 2017 Feb;25(2):294-297.
20 Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol. 2003 Dec 15;66(12):2333-40.
21 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
22 The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol. 2000 Dec;50(6):573-80.
23 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
24 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
25 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
26 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
27 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
28 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
29 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
30 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
31 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
32 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
33 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
34 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
35 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
36 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
37 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
38 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
39 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
40 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
41 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
42 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
43 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
44 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
45 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
46 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
47 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
48 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
49 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
50 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
51 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
52 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
53 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
54 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
55 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
56 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
57 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
58 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
59 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
60 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
61 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
62 Drug Interactions Flockhart Table
63 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
64 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
65 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
66 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
67 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
68 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
69 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
70 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
71 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
72 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
73 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
74 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
75 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
76 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
77 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
78 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
79 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
80 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
81 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
82 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
83 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
84 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
85 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
86 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
87 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
88 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
89 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
90 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
91 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
92 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
93 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
94 Drugs that may have potential CYP2B6 interactions.
95 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
96 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
97 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
98 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
99 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
100 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
101 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
102 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
103 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
104 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
105 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
106 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
107 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
108 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
109 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
110 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
111 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
112 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
113 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
114 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
115 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
116 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
117 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
118 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
119 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
120 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
121 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
122 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
123 Aranow AB, Hudson JI, Pope HG, et al "Elevated antidepressant plasma levels after addition of fluoxetine." Am J Psychiatry 146 (1989): 911-3. [PMID: 2787124]
124 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
125 Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96. [PMID: 8930024]
126 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
127 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
128 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
129 Canadian Pharmacists Association.
130 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
131 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
132 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
133 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
134 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
135 Cerner Multum, Inc. "Australian Product Information.".
136 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
137 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
138 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
139 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
140 Burke MS, Josephson A, Lightsey A "Combined methylphenidate and imipramine complication." J Am Acad Child Adolesc Psychiatry 34 (1995): 403-4. [PMID: 7751253]
141 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
142 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
143 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
144 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
145 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
146 Multum Information Services, Inc. Expert Review Panel.
147 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
148 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
149 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
150 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
151 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
152 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
153 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
154 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
155 Fogelson DL "Fenfluramine and the cytochrome P450 system." Am J Psychiatry 154 (1997): 436-7. [PMID: 9054800]
156 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
157 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
158 Brosen K, Kragh-Sorensen P "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit 15 (1993): 258-60. [PMID: 8333008]
159 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
160 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
161 Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9. [PMID: 10750939]
162 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
163 Abernethy DR, Greenblatt DJ, Shader RI "Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability." J Pharmacol Exp Ther 229 (1984): 702-5. [PMID: 6726654]
164 Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
165 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
166 Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
167 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
168 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
169 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
170 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
171 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
172 Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
173 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
174 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
175 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
176 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
177 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
178 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
179 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
180 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
181 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
182 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
183 Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
184 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
185 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
186 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
187 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
188 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
189 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
190 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
191 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
192 Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
193 Bruckner HW, Schleifer SJ "Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction." Cancer Treat Rep 67 (1983): 516. [PMID: 6406063]
194 Tofanetti O, Albiero L, Galatulas I, Genovese E "Enhancement of propoxyphene-induced analgesia by doxepin." Psychopharmacology (Berl) 51 (1977): 213-5. [PMID: 402676]
195 Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
196 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
197 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
198 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
199 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
200 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
201 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
202 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
203 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
204 Alter P, Tontsch D, Grimm W "Doxepin-induced torsade de pointes tachycardia." Ann Intern Med 135 (2001): 384-5. [PMID: 11529713]
205 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
206 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
207 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
208 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
209 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
210 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
211 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]